We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

688002:SSERaytron Technology Co., Ltd. Class A Analysis

Data as of 2026-03-17 - not real-time

CN¥101.82

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Raytron Technology is trading just above its identified support of 101.68 CNY with the 20‑day SMA (111.23) still above the 50‑day SMA (108.93), confirming a longer‑term bullish bias. However, the RSI of 37 signals near‑oversold conditions and the MACD histogram remains bearish (-1.54), suggesting short‑term downside pressure. The stock’s valuation is stretched, posting a trailing PE of 58.9 versus an industry average of 34.2 and a price‑to‑book of 7.4, while revenue has surged nearly 92% YoY. Volatility is high at over 43% (30‑day) but beta is low (Fundamentally, the company delivers solid margins (operating margin ~11%, profit margin ~17%) and a healthy ROE of 18.7%, yet cash generation appears weak (zero operating and free cash flow). Debt is modest (DE ratio ~25%) and the dividend is minimal (<0.2%) with a low payout ratio, making the dividend sustainable but not a primary attraction. Given the mix of strong growth, elevated valuation, and mixed technical signals, investors should weigh short‑term price risk against medium‑ to long‑term upside from the company’s expanding infrared and MEMS product portfolio.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and RSI near oversold
  • Price close to support level
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Robust revenue growth (~92% YoY)
  • Strong operating and profit margins
  • Low systematic risk (beta <0.2)

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Expanding addressable market in infrared and MEMS sensors
  • Sustainable dividend with low payout ratio
  • Long‑term bullish trend indicated by moving averages

Key Metrics & Analysis

Financial Health

Revenue Growth91.80%
Profit Margin17.41%
P/E Ratio58.9
ROE18.66%
Debt/Equity25.31
P/B Ratio7.4
Industry P/E34.2

Technical Analysis

TrendBullish
RSI37.2
SupportCN¥101.68
ResistanceCN¥121.98
MA 20CN¥111.23
MA 50CN¥108.93
MA 200CN¥82.30
MACDBearish
VolumeStable
Fear & Greed Index79.45

Valuation

GradeOvervalued
TypeBlend
Dividend Yield0.15%

Risk Assessment

Beta0.17
Volatility43.57%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.